DL
Dennis M Lanfear
President & CEODirector

Dennis M Lanfear insider trades: Coherus Oncology (CHRS) stock sales

President & CEO, Coherus Oncology Last trade Nov 22, 2023 44 Form 4 filings
$0
Sold, last 12 months
0 sales
$0
Bought, last 12 months
0 buys
9
Open-market trades
since 2015
2
Companies
last trade 2023

Trades on the price chart

Daily close, with an arrow on each day they bought or sold

Companies

Where Dennis reports to the SEC

Open-market buys and sales

9 trades reported on SEC Form 4, newest first

DateStockTypeValue
Nov 22, 2023CHRS↓ Sell$450K
Jun 8, 2021CHRS↓ Sell$421K
Nov 21, 2019CHRS↓ Sell$232K
Nov 20, 2019CHRS↓ Sell$14.8M
May 30, 2019CHRS↓ Sell$631K
May 16, 2018CHRS↓ Sell$341K
Sep 21, 2016CHRS↓ Sell$129K
Sep 16, 2016CHRS↓ Sell$92K
Nov 30, 2015CHRS↓ Sell$13K

Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.

About Dennis M Lanfear's insider trades

Dennis M Lanfear is President & CEO at Coherus Oncology (CHRS). Since Nov 30, 2015, Dennis has reported no open-market purchases and 9 sales worth $17.2M on SEC Form 4. There have been no open-market trades in the last 12 months.

Their filings also include grants and awards (24 filings), shares withheld for taxes (8 filings), option exercises (4 filings), gifts (3 filings). These aren't open-market trades and aren't counted above.

How to read insider trades

Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every CHRS insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.